Behnaz Bayat

Dr. Behnaz Bayat


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
BBBehnaz Bayat
Behnaz Bayat
KNKaspar René Nielsen
Kaspar René Nielsen
GBGregor Bein
Gregor Bein
ATAnnalena Traum
Annalena Traum
MBMonika Burg-Roderfeld
Monika Burg-Roderfeld
USUlrich J. Sachs
Ulrich J. Sachs
Transfusion-related lung injury (TRALI) is a serious side effect of blood transfusion. Exclusion of antibody carriers from the donor pool has significantly decreased the number of cases, but TRALI remains the leading cause of transfusion-related morbidity and mortality in industrialized countries. Here, we show that proteins released from donor cells during processing of blood components are capable of inducing a new type of reverse TRALI when transfused to preimmunized recipients. First, we show that soluble neutrophil surface protein CD177 in complex with proteinase 3 (sCD177/PR3) is not only present in human plasma but also in packed red blood cell (PRBC) supernatant. Filtration or storage enhances the concentration of sCD177/PR3 in PRBCs. Second, we show that sCD177/PR3 specifically binds to PECAM-1 on stimulated (but not on unstimulated) endothelial cells (ECs). Third, we provide evidence that the sCD177/PR3/PECAM-1 complex is functional. In the presence of monoclonal or human antibodies against CD177 or PR3, ECs produce reactive oxygen species and become apoptotic. Albumin flux through an EC monolayer increases significantly whenever antibodies and the cognate antigens are present. Finally, we describe a clinical case in which anti-CD177 present in a transfusion recipient precipitated TRALI after the transfusion of CD177-positive, but not CD177-negative, PRBCs. In conclusion, we introduce a new TRALI mechanism based on the specific binding of transfused, soluble antigens to activated ECs in preimmunized recipients. We suggest that further studies and clinical work-up of TRALI should also include antibody investigation of the recipient.


3 March 2019 in Transfusion
Verified
Journal Article
Closed access
PDF file
JWJianming Wu
Jianming Wu
YLYunfang Li
Yunfang Li
RSRandy M. Schuller
Randy M. Schuller
LLLing Li
Ling Li
ALAnne‐Sophie Litmeyer
Anne‐Sophie Litmeyer
BBBehnaz Bayat
Behnaz Bayat

18 March 2021 in Transfusion
Verified
Journal Article
Open access
PDF file
ATAnnalena Traum
Annalena Traum
CHChristine Hofmann
Christine Hofmann
SHSabine Haas
Sabine Haas
SSSilke Schmidt
Silke Schmidt
GBGregor Bein
Gregor Bein
BBBehnaz Bayat
Behnaz Bayat
Background CD177 is a surface protein on neutrophils and a main mediator for the surface expression of proteinase 3 (PR3). Its functions are largely unknown. At least three types of antibodies have been described to target CD177: isoantibodies, which are formed in CD177‐null individuals as a result of an immune reaction following transfusion or pregnancy; autoantibodies present in sera from patients with autoimmune neutropenia; and antineutrophil cytoplasmic antibodies in sera from patients with glomerulonephritis with polyangiitis. In this study, we aimed to compare the binding characteristics of auto‐ and iso‐antibodies to optimize their detectability in the neutrophil serology laboratory. Study Design and Methods The reactivity of iso‐ and auto‐antibodies against CD177 was studied using granulocytes, “native” CD177/PR3 complex, and recombinant CD177 or PR3. Results All iso‐ and auto‐antibodies were reactive with CD177/PR3 when immobilized with monoclonal antibody (moab) 7D8. Seventy‐five percent of autoantibodies, but none of the isoantibodies, did not react with CD177/PR3 immobilized with moab MEM166. The majority of autoantibodies did not react with recombinant CD177, whereas most isoantibodies tested positive. Discussion Our results suggest that iso‐ and auto‐antibodies against CD177 target different epitopes. Isoantibodies mainly target CD177 alone, while the majority of autoantibodies target a native epitope present on the neutrophil surface, but absent from recombinant CD177 which lacks PR3. Moab MEM166 binds to the native epitope and hinders the binding of CD177 autoantibodies. The results may help to design diagnostic strategies, especially for the identification of autoantibodies.

6 October 2019 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
BBBehnaz Bayat
Behnaz Bayat
ATAnnalena Traum
Annalena Traum
HBHeike Berghöfer
Heike Berghöfer
SWSilke Werth
Silke Werth
JZJieging Zhu
Jieging Zhu
SSSentot Santoso
Sentot Santoso
Background Fetal/neonatal alloimmune thrombocytopenia (FNAIT) results from maternal alloantibodies (abs) reacting with fetal platelets expressing paternal human platelet antigens (HPAs), mostly HPA-1a. Anti-HPA-1a abs, are the most frequent cause of severe thrombocytopenia and intracranial hemorrhage (ICH). Objectives Titration of anti-HPA-1a in maternal serum using standard National Institute for Biological Standards and Control (NIBSC) 03/152 is one diagnostic approach to predict the severity of FNAIT. Recently, we found three anti-HPA-1a subtypes reacting with the β3 subunit independently or dependently from complexes with αIIb and αv. Endothelial cell-reactive anti-αvβ3 abs were found predominantly in cases with ICH. Our aim was to assess whether available standard material represents all anti-HPA-1a subtypes. Materials and Methods In this study, anti-HPA-1a sera (NIBSC 03/152) and human monoclonal antibodies (moabs) against HPA-1a (moabs 26.4 and 813) were evaluated using transfected cell lines expressing αIIbβ3, αvβ3 or monomeric cβ3. Results Flow cytometry analyses with well-characterized murine moabs recognizing αIIbβ3, αvβ3, or β3 alone demonstrated that AP3 reacts compound-independently, whereas compound-dependent moabs Gi5 and 23C6 reacted only with complexes. NIBSC 03/152, moabs 26.4, and 813 against HPA-1a reacted like AP3, same results were obtained with monomeric cβ3 in immunoblotting. Antigen capture assay targeting endothelial cells showed anti-HPA-1a reactivity disappearance after cβ3 beads adsorption. Furthermore, in contrast to anti-HPA-1a abs from ICH cases, none of NIBSC 03/152, 26.4, and 813 inhibited tube formation. Conclusion These results suggest that current anti-HPA-1a standard material contains only the anti-β3 subtype. The absence of anti-αvβ3 makes NIBSC 03/152 less suitable as standard to predict the severity of FNAIT.

7 February 2022 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
BEBehnaz Esmaeili
Behnaz Esmaeili
BBBehnaz Bayat
Behnaz Bayat
AAAtefe Alirezaee
Atefe Alirezaee
MDMona Delkhah
Mona Delkhah
MMMohammad Reza Mehdizadeh
Mohammad Reza Mehdizadeh
ZPZahra Pourpak
Zahra Pourpak
Objective. Human neutrophil antigens (HNAs) can be targeted by HNA-allo antibodies and cause a variety of clinical conditions such as transfusion-related acute lung injury (TRALI) and neonatal alloimmune neutropenia (NAIN). The current study is aimed at identifying the genotype and allele frequencies of HNAs in Iranian blood donors. Methods. A total of 150 blood samples were obtained from healthy blood donors. HNA-1, HNA-3, HNA-4, and HNA-5 were genotyped, using the polymerase chain reaction sequence-specific primer (PCR-SSP) technique. The expression of the HNA-2 antigen on the neutrophil surface was evaluated by flow cytometry. Results. The allele frequencies of FCGR3B1 (encoding HNA-1a), FCGR3B2 (encoding HNA-1b), and FCGR3B3 (encoding HNA-1c) were 0.34, 0.63, and 0.03, respectively. For HNA-3, the allele frequencies for SLC44A21 (encoding HNA-3a) and SLC44A22 (encoding HNA-3b) were 0.63 and 0.37, respectively. The frequencies of ITGAM1 (encoding HNA-4a) and ITGAM2 (encoding HNA-4b) alleles were 0.85 and 0.15, respectively. Furthermore, the frequencies of ITGAL1 (encoding HNA-5a) and ITGAL2 (encoding HNA-5b) alleles were 0.72 and 0.28, respectively. In the studied population, HNA-2 antigen was present on the neutrophil surface in 97.3% of the individuals, while no detectable HNA-2 expression was observed in 2.7% of the individuals. However, no significant difference in HNA-2 expression between different age groups was found. Conclusion. The present study provides the first report of the HNA allele and genotype frequencies among the Iranian population. All HNAs (HNA-1 to HNA-5) were typed using the PCR-SSP and flow cytometer. In the current cohort study, the determined HNA allele frequencies were similar to the previous reports from British, German, and Danish populations. Considering the presence of different Iranian ethnic groups, further studies with a larger sample size are needed to draw a total picture for HNA allele frequencies.